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Adiponectin deficiency increases leukocyteendothelium interactions via upregulation of
endothelial cell adhesion molecules in vivo
Raogo Ouedraogo,1 Yulan Gong,2 Brett Berzins,2 Xiandong Wu,1 Kalyankar Mahadev,1
Kelly Hough,1 Lawrence Chan,3 Barry J. Goldstein,1 and Rosario Scalia2
1Division of Endocrinology, Diabetes, and Metabolic Diseases, Department of Medicine, and 2Department of Molecular
Physiology and Biophysics, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
3Section of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

This study reports on what we believe are novel mechanism(s) of the vascular protective action of adiponectin.
We used intravital microscopy to measure leukocyte-endothelium interactions in adiponectin-deficient (Ad–/–)
mice and found that adiponectin deficiency was associated with a 2-fold increase in leukocyte rolling and a
5-fold increase in leukocyte adhesion in the microcirculation. Measurement of endothelial NO (eNO) revealed
that adiponectin deficiency drastically reduced levels of eNO in the vascular wall. Immunohistochemistry demonstrated increased expression of E-selectin and VCAM-1 in the vascular endothelium of Ad–/– mice. Systemic
administration of the recombinant globular adiponectin domain (gAd) to Ad–/– mice significantly attenuated
leukocyte-endothelium interactions and adhesion molecule expression in addition to restoring physiologic levels of eNO. Importantly, prior administration of gAd also protected WT mice against TNF-α–induced
leukocyte-endothelium interactions, indicating a pharmacologic action of gAd. Mechanistically, blockade of
eNOS with Nω-nitro-l-arginine methyl ester (l-NAME) abolished the inhibitory effect of gAd on leukocyte
adhesion, demonstrating the obligatory role of eNOS signaling in the antiinflammatory action of gAd. We
believe this is the first demonstration that gAd protects the vasculature in vivo via increased NO bioavailability
with suppression of leukocyte-endothelium interactions. Overall, we provide evidence that loss of adiponectin
induces a primary state of endothelial dysfunction with increased leukocyte-endothelium adhesiveness.
Introduction
Adiponectin is an adipocyte-derived protein with insulin-sensitizing, antiinflammatory, and antiatherogenic properties, abundantly
found in the plasma in various oligomeric forms (1, 2). In general,
decreased plasma levels of adiponectin have been associated with
obesity, a well-known risk factor for cardiovascular disease (3),
type 2 diabetes (4), and hypertension (5) although no study to date
has implicated specific adiponectin isoforms in these conditions.
Accordingly, plasma adiponectin levels are significantly lower in
patients with coronary artery disease, further suggesting that physiologic levels of adiponectin are necessary to maintain the normal,
noninflammatory phenotype of the vascular wall (4, 6). In agreement with these clinical observations, adiponectin-deficient (Ad–/–)
mice develop inflammatory-type vascular disorders in response to
mechanical injury. Thus, severe neointimal thickening and increased
proliferation of vascular smooth muscle cells occur in arteries of
Ad–/– mice following external cuff injury (7). Notably, restoration
of physiologic levels of adiponectin by recombinant adenovirus
transduction in vivo was shown to attenuate neointimal proliferation in Ad–/– mice by reducing smooth muscle cell proliferation (8).
Recent data have linked the vascular protective role of adiponectin with preservation of endothelial cell function. Reduced
Nonstandard abbreviations used: Ad–/–, adiponectin-deficient (mouse); Ad+/–,
adiponectin-hemizygous (mouse); CAM, cell adhesion molecule; eNO, endothelial
NO; gAd, globular adiponectin domain; K-H, Krebs-Henseleit; l-NAME, Nω-nitro-larginine methyl ester.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 117:1718–1726 (2007). doi:10.1172/JCI29623.
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endothelial NO (eNO) availability at the vascular wall causes
endothelial dysfunction (9), and the dysfunctional endothelium
expresses a proinflammatory phenotype characterized by elevated
expression of atherogenic cell adhesion molecules (CAMs) (10),
in part due to loss of eNO (11). Upregulation of CAMs at the
endothelial cell surface initiates pathologic leukocyte–endothelial
cell interactions (12), which ultimately expose the vascular wall
and surrounding tissues to the damaging action of activated leukocytes. Ouchi and coworkers (13) showed that endothelium-dependent relaxation is impaired in Ad–/– mice, suggesting that loss of
adiponectin impairs eNO signaling. In addition, adiponectin has
been shown to enhance NO production in cultured endothelial
cells in vitro (14–16). Recent evidence has linked increased leukocyte-endothelium interactions in the microcirculation with
inflammatory signal activation and the vascular complications
of diabetes (17), a metabolic condition associated with reduced
levels of adiponectin (4). Indeed, in vitro studies demonstrate that
adiponectin exhibits antiinflammatory effects, including the suppression of TNF-α–induced adhesion molecule expression (18).
In the present work, we sought to address the following: (a)
the impact of adiponectin deficiency on baseline leukocyte–
endothelial cell interactions in the microcirculation in vivo; (b)
the effect of administration of globular adiponectin domain
(gAd) on leukocyte-endothelium interactions in Ad–/– mice as
well as in WT mice exhibiting TNF-α–induced vascular inflammation; and (c) the role of eNO in the vascular protective action
of adiponectin in vivo. Our results clearly demonstrate that loss
of adiponectin function induces endothelial dysfunction characterized by loss of eNO and increased leukocyte-endothelium
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Figure 1
Leukocyte-endothelium interactions in mouse peri-intestinal venules are
increased by endogenous adiponectin deficiency. (A) Leukocyte rolling
flux in WT mice and Ad–/– mice before and after treatment with human
recombinant gAd (25 μg, s.c., twice daily for 10 days). (B) Leukocyte
adhesion values under the same experimental conditions. Data are
expressed as the mean ± SEM. Numbers at the base of the bars indicate the number of mice studied in each group. Pharmacologically active
doses of gAd prevent abnormal leukocyte–endothelial cell interactions in
the microcirculation in the face of chronic adiponectin deficiency.

interactions. We also found that administration of gAd effectively preserves endothelial function in both acute inflammation
and states of chronic adiponectin deficiency.
Results
Adiponectin deficiency increases leukocyte-endothelium interactions. To
study the effect of adiponectin deficiency on vascular inflammation, we monitored basal leukocyte-endothelium interactions in
WT mice, mice completely lacking adiponectin (Ad–/–), and adiponectin-hemizygous (Ad+/–) mice. WT mice had endogenous total
adiponectin plasma levels in the range of 11 ± 0.8 μg/ml. In contrast, levels of total adiponectin were virtually undetectable in the
serum of Ad–/– mice (average values were 0.1 ± 0.1 μg/ml; P < 0.001
versus WT), confirming the functional phenotype of the adiponectin knockout mouse model used in our study (19). Following
administration of 25 μg gAd s.c. to Ad–/– mice, serum gAd levels
increased to 0.55 ± 0.1 μg/ml (n = 2). Ad+/– mice obtained by extensive (>15 generations) backcrossing of Ad–/– mice with WT C57BL/6J
mice showed a 58% reduction in total plasma adiponectin levels compared with WT mice (average values were 4.6 ± 1 μg/ml;
P < 0.01 versus WT and Ad–/–). Thus, unpairing of the adiponectin
gene induces the expression of intermediate phenotypes.
Intravital microscopy studies revealed a very low number of
rolling leukocytes in peri-intestinal venules of control WT mice
(Figure 1A). In contrast, Ad–/– mice exhibited a 2-fold increase
in the number of rolling leukocytes. Leukocyte rolling was
also increased in Ad+/– mice although to a lower degree than in
Ad–/– mice (Figure 1A). Moreover, leukocyte rolling velocities
(31.04 ± 1.50 μm/s in WT mouse venules) were reduced in Ad+/–
and Ad–/– mice, with the slowest leukocyte rolling velocity detected in Ad–/– mice (19.40 ± 0.44 μm/s; P < 0.01 versus WT; Figure 2).
These data demonstrate that reduced levels of serum adiponectin
are associated with progressively increased leukocyte-endothelium
interactions in the microcirculation.

A very low number of leukocytes were also found to adhere to the
vascular endothelium of WT mice (Figure 1B). Conversely, leukocyte adhesion increased 5-fold and 2.5-fold in Ad–/– mice and Ad+/–
mice (P < 0.01 and P < 0.05 versus WT, respectively). As shown in
Table 1, no physiologically meaningful differences in body weight,
blood glucose levels, mean arterial blood pressure, venular diameters, or total leukocyte counts were observed among the groups
of mice studied. However, leukocyte blood counts increased after
injection of the E-selectin blocking antibody 9A9, probably due to
mobilization of adhering leukocytes to the circulating blood compartment (20). Thus, under our experimental conditions, changes
in leukocyte-endothelium interactions were not due to alterations
in glucose metabolism, circulating leukocyte numbers, systemic
hemodynamic variables, or local rheologic factors.
Parallel experiments in isolated mouse aorta ex vivo demonstrated that the aortic endothelium of Ad–/– mice has significantly
increased adhesiveness to formyl-Met-Leu-Phe–activated human
monocytic cells. For these studies, 12 aortic segments from 3 mice
were studied in each group. The average number of monocytic
cells adhering to control aorta from WT mice was only 4.3 ± 0.4
cells per microscopic field. In contrast, a total of 10.1 ± 0.6 and
7.7 ± 0.7 cells per microscopic field adhered to aortic segments
isolated from Ad–/– and Ad+/– mice, respectively (P < 0.01 versus
WT aorta). These data are in agreement with data on leukocyte
adhesion obtained by intravital microscopy, and they demonstrate
that in the setting of declining levels of adiponectin, the vascular
endothelium develops a proadhesive phenotype widely affecting
large conduit vessels as well as the microcirculation.
gAd treatment attenuates leukocyte-endothelium interactions. To ascertain whether restoration of adiponectin signaling could reverse the
abnormalities in leukocyte-endothelium interactions observed in
Ad–/– mice, we treated Ad–/– mice with human recombinant gAd
for a period of 10 days, as described in Methods. Prior studies have
shown that gAd exhibits a variety of salutary effects in the vasculature, including reduction of oxidative stress in cultured endothelial
cells (16, 18, 21), and atheroprotective effects in the cardiovascular
system of the mouse, as recently reviewed by our group (22).
As measured by intravital microscopy, treatment with gAd normalized leukocyte rolling flux, leukocyte rolling velocity, and leukocyte adhesion to the values found in control WT mice (Figures 1
and 2). These data support the hypothesis that the vascular inflammation observed in states of adiponectin deficiency is amenable to
treatment with selected adiponectin isoforms, specifically gAd.
gAd treatment reverses TNF-α induced leukocyte-endothelium interactions
in WT mice. TNF-α is a circulating cytokine that induces endothelial
dysfunction characterized by downregulation of the eNOS/NO biosynthetic machinery (23–25) and upregulation of endothelial CAM
expression (11). Interestingly, adiponectin has been reported to
reverse some of the in vitro inflammatory signaling effects of TNF-α
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Figure 2
Endogenous adiponectin deficiency decreases leukocyte rolling velocity in the microcirculation. Panels illustrate rolling velocities in all experimental groups of mice. Data are expressed as the mean and represent the total leukocyte rolling frequency calculated from 5 mice in each group.
Treatment of Ad–/– mice with human recombinant gAd (25 μg, s.c., twice daily for 10 days) normalizes leukocyte rolling velocity (top, middle panel).
Similar results were obtained following functional blockade of E-selectin with the mAb 9A9 in Ad–/– mice (2.1 mg/kg, i.v.; bottom, right panel).

in cultured endothelial cells (6). Accordingly, we determined whether
pharmacologically active doses of gAd could inhibit TNF-α–mediated leukocyte-endothelium interactions in WT mice expressing
physiological levels of adiponectin. Two-hour exposure of the mouse
microcirculation to 1 μg/kg TNF-α given i.p. increased leukocyte
rolling 3-fold (P < 0.01; Figure 3A) and leukocyte adhesion 6-fold
(P < 0.01; Figure 3B). Treatment of mice with 2 consecutive doses
of gAd (25 μg/mouse, s.c.), given 24 hours and repeated 2.5 hours
before TNF-α administration, attenuated TNF-α–mediated leukocyte rolling by 2-fold and leukocyte adhesion by 3-fold (P < 0.01;
Figure 3). These data demonstrate that pharmacologically active doses
of gAd dramatically protect the vasculature against cytokine-induced
inflammation, even in the presence of endogenous adiponectin.

Endogenous adiponectin and gAd treatment regulates NO availability
in the vascular wall. To test the hypothesis that the antiinflammatory effect of adiponectin in the vasculature is accompanied by
enhanced availability of eNO, we measured eNO release from the
isolated mouse aorta. Adiponectin deficiency was associated with
a 40% reduction in NO production compared with that of control
WT mice (Table 2; P < 0.01 versus WT aorta). Similarly, 2 hours
after i.p. injection of 1 μg/kg of TNF-α into WT mice, eNO production in the aorta was reduced by 36% (Table 2; P < 0.01 versus
control WT mice). Treatment of Ad–/– mice with gAd for 6 consecutive days restored eNO production significantly toward the
level observed in WT mice (Table 2; P > 0.05 versus WT). The effect
of TNF-α to suppress eNO generation was also blocked by 55%

Table 1
Main metabolic and hemodynamic parameters in all experimental groups of mice
Group
(n)
WT (6)
WT + TNF-α (7)
WT + TNF-α + gAd (5)
WT + l-NAME (7)
WT + l-NAME + gAd (4)
Ad+/– (6)
Ad–/– (8)
Ad–/– + gAd (6)
Ad–/– + l-NAME + gAd (4)
Ad–/– + IgG1 (6)
Ad–/– + mAb 9A9 (6)

Blood glucose
(mg/dl)

MABP
(mmHg)

Wall shear
rate (s–1)

Average venule
diameter (μm)

Body weight
(g)

wbc
(106)

131 ± 6
137 ± 4
119 ± 6
121 ± 3
111 ± 5
127 ± 5
137 ± 5
126 ± 6
107 ± 6
113 ± 4
122 ± 7

86 ± 4
90 ± 4
94 ± 4
91 ± 3
101 ± 3
87 ± 2
89 ± 4
75 ± 6
98 ± 3
92 ± 4
94 ± 2

1745 ± 214
2129 ± 233
2430 ± 411
2749 ± 135
2125 ± 90
1830 ± 170
2084 ± 170
1624 ± 76
2661 ± 175
2234 ± 88
2453 ± 112

31.7 ± 2.0
27.6 ± 1.7
29.3 ± 1.3
28.3 ± 0.8
27.3 ± 0.9
29.0 ± 1.8
25.8 ± 0.8
32.8 ± 1.6
32.5 ± 0.6
26.7 ± 0.3
24.3 ± 0.5

31 ± 1
26 ± 1
27 ± 1
28 ± 0
26 ± 1
28 ± 2
26 ± 1
26 ± 1
33 ± 2
29 ± 1
28 ± 1

6.0 ± 0.6
5.3 ± 0.5
5.7 ± 0.3
6.3 ± 1.2
5.1 ± 0.3
5.6 ± 0.6
5.4 ± 0.7
5.7 ± 0.5
6.3 ± 1.4
5.8 ± 0.5
7.0 ± 0.9

MABP, mean arterial blood pressure.
1720
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Figure 3
Pharmacologically active doses of gAd reverse TNF-α–induced leukocyte-endothelium interactions in WT mice. As shown in A and B, 1 μg/kg
TNF-α given 2 hours before the experiment increases leukocyte rolling
flux and leukocyte adhesion, respectively, in the microcirculation of WT
mice. Two 25 μg doses of gAd given 24 hours and 2.5 hours before
intravital microscopy significantly attenuates TNF-α–induced leukocyte
rolling and adhesion, confirming the potent antiinflammatory action of
pharmacologic doses of gAd also in mice expressing physiologic adiponectin levels. Data are expressed as the mean ± SEM. Numbers at
the base of the bars indicate the number of mice studied in each group.

with prior treatment with a double dose of 25 μg gAd, given as
described above. These data clearly demonstrate that pharmacologically active doses of gAd increase NO bioavailability not only
in states of adiponectin deficiency but also in the context of normal adiponectin levels when the cardiovascular system is exposed
to elevated cytokine levels.
In vivo eNOS blockade suppresses the antiinflammatory action of gAd.
To further substantiate the involvement of eNO availability in
the vascular protective action of adiponectin, we blocked eNOS
activity with the specific inhibitor Nω-nitro-l-arginine methyl ester
(l-NAME). In agreement with previous publications (26, 27),
superfusion of the mesenteric microcirculation with 1 mM
l-NAME increased leukocyte adherence 5-fold (P < 0.01 versus
control; Figure 4), thus producing an inflammatory signal comparable to that observed after injection of TNF-α (Figure 3).
l-NAME–induced leukocyte adherence was not affected by systemic
treatment of WT mice with recombinant gAd (Figure 4). Moreover,
l-NAME superfusion abolished the inhibitory effect of gAd treatment on leukocyte adhesion in Ad–/– mice (Figure 4). These results
demonstrate that functional eNOS activity is integrally involved in
the antiinflammatory actions of gAd in the vasculature in vivo.
Endogenous adiponectin and gAd treatment regulate expression of
endothelial CAMs: functional implications. To identify the underlying
molecular mechanism(s) responsible for the increased leukocyteendothelium interactions observed in states of adiponectin deficiency, we used immunohistochemistry to measure expression
levels of E-selectin and VCAM-1, 2 proinflammatory endothelial
CAMs known to regulate leukocyte halting and leukocyte firm
adhesion in the microcirculation. The percentage of venules
staining positively for E-selectin in ileal sections from WT mice
was consistently low (Figure 5). However, Ad –/– and Ad+/– mice
exhibited a significantly increased expression of E-selectin as
quantified by the percentage of positively staining venules.

Increased E-selectin expression on the venular endothelium of
Ad–/– mice was attenuated by gAd treatment (Figure 5). Similarly,
few ileal venules stained positive for VCAM-1 in WT control mice
(Figure 5). The number of ileal venules staining positive for
VCAM-1 expression increased in Ad +/– mice and Ad –/– mice.
Furthermore, treatment with gAd attenuated the expression of
VCAM-1 in ileal venules of Ad–/– mice (Figure 5).
Previous studies have implicated E-selectin in both leukocyte
rolling and leukocyte adhesion (28, 29). Accordingly, we sought to
investigate the contribution of E-selectin to leukocyte adhesion in
our Ad–/– mouse model by acutely blocking E-selectin function with
a bolus injection of the E-selectin mAb 9A9 to Ad–/– mice. Following
systemic administration of the mAb 9A9, leukocyte adhesion in Ad–/–
mice was drastically reduced (Figure 6A), demonstrating that
E-selectin is largely responsible for leukocyte adhesion in states of
adiponectin deficiency. Leukocyte rolling values in Ad–/– were slightly increased following administration of mAb 9A9 although they
failed to reach statistical significance (Figure 6B). Nonetheless, treatment with mAb 9A9 significantly increased leukocyte rolling velocity in Ad–/– mice from 19.3 ± 1.4 μm/s to 35.6 ± 2.9 μm/s (Figure 2).
Together, these data strongly correlate with the functional changes
in leukocyte-endothelium interactions shown in Figures 1 and 2.
They also emphasize the role of E-selectin in the vascular inflammation associated with adiponectin-deficient states.
Discussion
This study was undertaken to investigate the early mechanisms
of endothelial dysfunction associated with systemic adiponectin
deficiency, an area of growing interest given the high incidence of
vascular disease in metabolic states associated with obesity and
Table 2
Release of NO
Group (n)
WT (3)
WT + TNF-α (3)
WT + gAd + TNF-α (3)
Ad–/– (3)
Ad–/– + gAd (3)

NO (pmol/mg tissue)
142.4 ± 6.3
90.7 ± 7.8A
119.2 ± 6.9B
84.8 ± 4.7A
120.2 ± 7.9C

NO release was measured in isolated mouse aortic rings obtained from
WT or Ad–/– mice given 0.9% saline or TNF-α i.p. (1 μg/kg, injected 2
hours before isolation of aortas). In the gAd-treated WT mouse group, mice
were injected s.c. with 25 μg of gAd/mouse 24 hours before and again 2.5
hours before isolation of aortic rings. In the gAd-treated Ad–/– mouse group,
mice were injected s.c. with 25 μg of gAd/mouse given twice a day for 6
consecutive days. All values were obtained from 3 mice in each group.
Three aortic segments were studied in each mouse. AP < 0.01 versus WT;
BP < 0.05 versus WT + TNF-α; CP < 0.05 versus Ad–/–.

The Journal of Clinical Investigation    http://www.jci.org    Volume 117    Number 6    June 2007

1721

research article
Figure 4
Functional eNOS activity is necessary for the antiinflammatory
effect of gAd. Superfusion of the mouse mesenteric microcirculation
with the eNOS inhibitor l-NAME increases leukocyte adhesion in
WT mice (white bars). Two 25 μg doses of gAd given 24 hours and
2.5 hours before intravital microscopy failed to prevent leukocyte
adhesion in response to l-NAME. Moreover, attenuation of leukocyte adhesion by administration of gAd (25 μg/twice daily for 6 consecutive days) to Ad–/– mice is acutely hampered by superfusion of
the microcirculation with l-NAME (black bars). Data are expressed
as the mean ± SEM. Numbers at the base of the bars indicate the
number of mice studied in each group.

adiponectin overexpression protects ApoE-deficient mice from
atherosclerosis (41). Evidence has been also published to show
that circulating adiponectin binds to the vascular wall of catheter-injured vessels, although the functional implications of this
observation for vascular homeostasis are not known (42). More
mechanistic studies in vitro have demonstrated that this adipokine is provided with antiinflammatory properties against oxidative stress and the action of cytokines (18, 43), suggesting that
inhibition of inflammatory signals is the fundamental mechanism
of the vascular protective actions of adiponectin in vivo.
Our data demonstrating that adiponectin deficiency increases
leukocyte rolling and leukocyte adhesion help to explain a key
mechanism by which loss of physiologic levels of adiponectin
causes a generalized state of chronic vascular inflammation in vivo.

adipocyte dysfunction. We believe our results are the first in vivo
demonstration that global adiponectin deficiency increases leukocyte-endothelial cell interactions via reduced availability of eNO at
the vascular wall and upregulation of endothelial CAMs that are relevant to vascular inflammation and atherosclerosis. We also provide
evidence that systemic administration of pharmacologically active
doses of the recombinant gAd fragment alone reverts the endothelial
dysfunction associated with adiponectin deficiency and attenuates
cytokine-induced vascular inflammation in WT mice expressing
physiologic concentrations of adiponectin in the blood.
Recruitment of circulating leukocytes is important in
the pathophysiology of macrovascular (30) and microvascular diseases (17). The healthy endothelium does not
bind circulating leukocytes under normal conditions. In
the early stages of endothelial dysfunction, there is an
increase in endothelial cell expression of various adhesion
molecules on the luminal surface, including selectins and
CAMs, all of which act as receptors for glycoconjugates
and integrins present on the circulating leukocytes (31).
Trafficking leukocytes are known to be detrimental to
the vessel wall and tissues (32). Traditionally, it has been
believed that prolonged exposure of the vascular endothelium to elevated circulating levels of metabolites or
inflammatory mediators, such as glucose, free fatty acids,
oxidized LDL, and cytokines, causes endothelial dysfunction by perturbing endothelial cell homeostasis. Recent
research, however, has emphasized the role of adipose tissue and the deranged secretory properties of adipocytes
in obesity as major causes of endothelial dysfunction (2).
Dysfunction of adipose tissue, such as that occurring in
obesity and insulin resistance, is characterized by systemic activation of inflammatory signals (33). Many of these
signals arise directly or indirectly from secretory products
of white adipocytes and actively contribute to the circu- Figure 5
lating milieu that induces vascular dysfunction (34, 35).
Adiponectin deficiency increases E-selectin and VCAM-1 expression levels in
The reduction of circulating adiponectin levels in obe- the vascular endothelium of the mouse microcirculation. Representative sections
sity and insulin resistance (4, 36) is of particular interest of ileal venules (Vs) staining positive for E-selectin are shown in the top 3 photoin view of the fact that low adiponectin levels are associ- micrographs. E-selectin staining in all experimental groups of mice was detected
by avidin/biotin immunoperoxidase technique seen as brown reaction product
ated with endothelial dysfunction in humans (14, 37, 38).
(arrows). Original magnification, ×500. Bottom graphs show quantification of the
This observation has been confirmed in several relevant percentage of venules staining positive for E-selectin (left) and VCAM-1 (right).
animal models of disease in which reduced blood levels Values are mean ± SEM. Numbers at base of bars indicate the number of mice
of adiponectin have been proven to exacerbate vascular studied in each group. Five tissue sections were studied in each mouse, and
injury (8, 39, 40). In vivo studies have also proven that 50 venules were analyzed per section.
1722
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Figure 6
E-selectin supports leukocyte adhesion in the Ad –/– microcirculation. (A) Leukocyte adhesion in Ad–/– mice before and after in vivo
blockade of E-selectin with the E-selectin function–blocking mAb 9A9
(2.1 mg/kg). Leukocyte adhesion was not affected by systemic administration of control IgG1 (2.1 mg/kg). Leukocyte rolling values in Ad–/–
were slightly increased following administration of mAb 9A9, although
they failed to reach statistical significance (B). Values represent the
mean ± SEM of rolling or adherent leukocytes. Numbers at the base of
the bars indicate the number of mice studied for each group.

Specific adhesion molecules expressed on endothelial cells orchestrate the recruitment of circulating leukocytes under physiologic
and pathophysiologic conditions. We found evidence of increased
leukocyte rolling flux associated with reduced leukocyte rolling
velocities and increased leukocyte adhesion (Figures 1 and 2) in
the microcirculation of Ad–/– mice. Accordingly, we measured the
expression of E-selectin and VCAM-1 in the Ad–/– vascular endothelium and found evidence of increased E-selectin and VCAM-1
expression in Ad–/– mice. Upregulation of E-selectin reduces rolling velocities of leukocytes (20) and participates in the conversion of rolling to firm adhesion, as demonstrated by the fact that
E-selectin–deficient mice have a reduced number of firmly adherent leukocytes in response to local chemoattractant (28) or
cytokine stimulation (29). To determine whether the increased
adhesion of leukocytes seen in Ad–/– mice is functionally dependent
on E-selectin, we blocked E-selectin function in vivo with a mAb.
Consistent with the previous studies cited above, we found that
blockade of E-selectin function in Ad–/– acutely increased leukocyte rolling velocity and inhibited leukocyte adhesion in the face of
adiponectin deficiency. Taken together, these data highlight a role
for E-selectin in the endothelial dysfunction and vascular inflammation associated with loss of physiologic levels of adiponectin.
The type I transmembrane glycoprotein VCAM-1 was also found
to be upregulated in the vascular endothelium of mice deficient in
adiponectin. VCAM-1 expression is very low or absent under physiologic conditions, and its expression levels can be rapidly induced
by cytokines, such as TNF-α (31). VCAM-1 has been implicated
in the process of atherogenesis and plaque formation both in the
mouse and in humans (44, 45). Relevant to our study, VCAM-1
mediates firm adhesion of leukocytes by functioning as a counterreceptor to leukocyte integrins (46). Our functional studies demonstrated that leukocyte adhesion in the microcirculation of Ad–/–
mice is largely dependent on E-selectin. Thus, future research must
be undertaken to clarify whether VCAM-1 also plays a significant
role in the vascular inflammation associated with adiponectin

deficiency, since we clearly found evidence of increased VCAM-1
expression in this condition (Figure 5).
In addition to upregulating CAMs, the dysfunctional endothelium experiences loss of eNO (11). Loss of eNO contributes to hypertension and several concomitant alterations, including increased
expression of endothelial adhesion molecules that underlie the
early processes of atherosclerosis (13–15). Overall, there is a consensus in the literature that the antiinflammatory action of eNO
is largely based on its inhibitory effect on leukocyte-endothelium
interactions. At the molecular level, NO suppresses leukocyteendothelium interactions by inhibiting exocytosis of Weibel-Palade bodies and modulating the activity of NF-κB (11, 47). Interestingly, induction of E-selectin by cytokines occurs exclusively at
the transcriptional level and requires proteasome-dependent activation of NF-κB for maximal expression (48). As with E-selectin,
activation of the NF-κB signal transduction pathway is essential
for cytokine-induced VCAM-1 expression (49). Adiponectin has
been shown to inhibit NF-κB activation in endothelial cells (6).
Here, we report that loss of circulating levels of adiponectin is
associated with reduced bioavailability of eNO. Thus, our results
clearly show that the presence of adiponectin in the mouse circulation contributes to maintaining the endogenous production of
eNO. Consistent with these results, our laboratory and others have
reported that adiponectin enhances NO production in cultured
endothelial cells (14–16).
Directly relevant to the clinical application of these data is our
finding that pharmacologically active doses of gAd almost completely reverse the increase in leukocyte-endothelium interactions
observed in both Ad–/– mouse vasculature and WT mouse vasculature acutely inflamed with TNF-α. Several adiponectin multimeric isoforms, in addition to full-length adiponectin, have been
isolated in the blood and tissues of humans and laboratory animals
(1, 2). Recent research has emphasized a role for the gAd fragment
that is now known to have metabolic as well as vascular protective
functions (40, 50). Indeed it has been hypothesized that gAd may
circulate in the blood of humans at a very low concentration or
processed from the full-length protein at a local site (50), although
no definitive evidence has been provided. This fragment of adiponectin has also been hypothesized to be a pharmacologically potent
form of adiponectin that may be generated by a proteolytic cleavage
step in vivo, although work in this area is ongoing (2, 50). In support of a potential therapeutic role for gAd, however, our results
show that gAd treatment affords significant pharmacological protection against vascular inflammation at concentrations well below
those of the physiological levels of circulating full-length adiponectin complexes. At the molecular level, we found evidence that gAd
attenuates expression levels of E-selectin and VCAM-1 in Ad–/– mice,
a result that agrees with our functional observation demonstrating
reduced leukocyte adhesion following gAd therapy in the mouse.
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Mechanistically, we also found evidence that gAd increases availability of eNO in Ad–/– mice and that blockade of eNOS enzyme
activity with l-NAME abolishes the inhibitory effect of adiponectin
on leukocyte endothelium interactions. Indeed, in TNF-α–treated
mice, gAd increased aortic eNO levels by approximately 50% while
leukocyte–endothelial cell interaction in the mesenteric microcirculation was almost completely blocked. The apparent discrepancy
between the antiinflammatory effect of gAd in the microcirculation and its eNO augmenting action in the aorta could be due in
part to different sensitivities of microvascular and macrovascular
endothelia to the NO potentiating action of gAd. Future studies
on gAd receptor distribution and activity in different vasculatures
are needed to fully understand the impact of adiponectin in the
homeostasis of individual vascular beds. Taken together, these data
clearly demonstrate that an eNO-related mechanism is involved in
the vascular protective action of adiponectin.
The antiinflammatory action of gAd was also confirmed in the
WT mouse vasculature inflamed with a clinically relevant cytokine
such as TNF-α. In fact, TNF-α/NF-κB signaling is well recognized as a strong regulator of inflammation in the vasculature
in humans (51). Relevant to this view, cytokines such as TNF-α
are closely linked to the endothelial production of ROS (superoxide and H2O2), a central component of the inflammatory milieu
that contributes to atherogenesis in some pathologic conditions
(52–54). ROS can quickly quench NO, a process that results in
the formation of peroxynitrite, which has also been postulated to
alter the catalytic activity of eNOS, diverting its synthesis from
NO toward increased superoxide production (55). In addition,
TNF-α directly downregulates basal and insulin-stimulated eNOs
expression (56). Recent work has shown in vitro that gAd stimulation of NO generation is associated with enhanced eNOS complex
formation with HSP90 (57). In agreement with this view, a recent
study in vitro has demonstrated that full-length adiponectin suppresses TNF-α–induced adhesion molecule expression in cultured
endothelial cells (18). We have also previously shown suppression
of ROS by gAd in cultured endothelial cells treated with oxidized
LDL or high glucose (16, 28). However, additional studies are
needed to further elucidate the potential pharmacological effects
of various adiponectin isoforms, including multimers and adiponectin fragments such as gAd in vascular inflammation.
In summary, our data demonstrate a clear role for physiologic levels of adiponectin in the regulation of eNO bioavailability
and leukocyte-endothelium interactions in vivo. They also demonstrate that the abnormal endothelial dysfunction occurring in
pathologic conditions associated with adiponectin deficiency is
amenable to gAd pharmacologic treatment.
Methods
Animal models and study protocols. This study was performed in accordance
with NIH guidelines for the use of experimental animals. The Institutional
Animal Care and Use Committee of Thomas Jefferson University approved
all of the animal protocols. WT C57BL/6J mice were purchased from
Charles River Laboratories. Ad–/– mice, extensively backcrossed to C57BL/6J
controls, were generated and characterized as reported (19). Ad+/– mice
were obtained by backcrossing Ad–/– with WT mice. In all reported experiments, male mice were studied at age 12–17 weeks. The role of adiponectin
deficiency and gAd therapy on leukocyte-endothelium interactions was
studied in the following 4 groups of mice: (a) WT mice given saline; (b)
Ad–/– mice given saline; (c) Ad+/– mice given saline; and (d) Ad–/– mice given
gAd of 25 μg twice daily for 10 consecutive days. The inhibitory action of
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gAd (25 μg given 24 hours and repeated 2.5 hours before experiment) on
leukocyte-endothelium interactions was also studied in WT mice injected
with 1 μg/kg TNF-α i.p. 2 hours before experiment. In parallel experiments, the microcirculation of WT and Ad–/– mice was superfused with
1 mM l-NAME to study the role of eNOS activity in the mechanism by
which gAd inhibits leukocyte-endothelium interactions. l-NAME has been
used before to induce leukocyte-endothelium interactions in the microcirculation (12). In additional studies, Ad–/– mice were given 2 mg/kg i.v. of the
E-selectin function–blocking antibody 9A9 or control IgG1 to determine
the contribution of E-selectin to the increased leukocyte adhesion seen in
states of adiponectin deficiency. Previous studies have demonstrated that
mAb 9A9 efficiently blocks E-selectin function in the mouse (28, 58). In
all experiments, pharmacologically active doses of gAd were delivered to
the mouse via s.c. injection. Previous studies have shown that adiponectin
injected s.c. is absorbed into the systemic circulation (59).
Fluorescence intravital microscopy of mouse peri-intestinal venules. Mice were
anesthetized by i.p. injection of 70 mg/kg sodium pentobarbital. Additional sodium pentobarbital was administered i.v. as needed during the intravital microscopy observation time. Polyethylene catheters were inserted into
the left carotid artery to monitor mean arterial blood pressure and into the
right jugular vein for administration of saline, pentobarbital, rhodamine,
and antibodies. A loop of ileal mesentery was exteriorized through a midline incision in the abdominal wall and placed in a temperature-controlled,
fluid-filled Plexiglas chamber (developed in our laboratory) for observation
of the peri-intestinal microcirculation by intravital microscopy. The ileum
and mesenteric tissue were superfused throughout the experiment with a
modified Krebs-Henseleit (K-H) buffer warmed to 37°C and bubbled with
95% N2/5% CO2. Centerline red blood cell velocity (Vrbc) was monitored in
bright field using an optical Doppler velocimeter (Department of Systems
Biology and Translational Medicine, Texas A&M University System Health
Science Center). Vrbc and venular diameter (D) were used to calculate the
venular wall shear rate (γ) with the following formula: γ = 4.9×8(Vmean/D),
where mean velocity of red blood cells (Vmean) equals Vrbc/1.6 (60).
Postcapillary venules (20- to 40-μm diameter) were observed under fluorescence microscopy, using a previously described intravital microscopy
unit (61). Leukocytes were fluorescently labeled in vivo by injection of
0.3 mg/kg Rhodamine 6G (Sigma-Aldrich) injected via the right jugular vein.
Rhodamine 6G–labeled leukocytes were monitored at a final magnification
of ×400 using appropriate filter sets. The microscopic images were recorded on an IBM computer equipped with Image-Pro software (version 4.5;
MediaCybernetics). Leukocytes were classified according to the quality or
duration of their interaction with the venular wall as rolling or adherent.
The leukocyte rolling flux was defined as the total number of leukocytes
crossing the 100-μm venular segment in 60 seconds at a velocity that was
significantly lower than the centerline velocity. Leukocyte rolling velocity was determined by measuring the time required for a leukocyte to roll
along a 100-μm length of venule. Leukocytes that were stationary for more
than 30 seconds were defined as adherent. Leukocyte adhesion is expressed
as the number of cells/100 μm of venular length. For experiments with
l-NAME, mice were allowed to stabilize for 30 minutes following surgery.
Following stabilization, a 20- to 40-μm–diameter postcapillary venule was
chosen for observation. A baseline recording was made to establish basal
values for leukocyte rolling and adherence. The mesentery was then superfused with 1 mM l-NAME dissolved in K-H solution for 60 minutes. Video
recordings were made at 0, 15, 30, 45, and 60 minutes after initiation of
superfusion for quantification of leukocyte rolling and adherence.
Adhesion of cultured monocytes to the mouse aorta in vitro. For these studies,
we used an in vitro adhesion assay previously described (62). In brief, the
thoracic aorta was isolated from donor WT and Ad–/– mice euthanized with
an overdose of sodium pentobarbital (150 mg/kg) injected i.p. The aorta
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was quickly removed and placed in cold, oxygenated PBS. After carefully
removing the adventitia, aortas were cut to 4-mm segments. The segments
were then carefully opened longitudinally and placed into culture dishes
containing 1 ml K-H solution with their luminal surfaces facing up.
Human monocytic cells (THP-1) were cultured in RPMI-16 (+2 mM
glutamine + 0.05 mM 2 mercaptoethanol + 10% FBS; Invitrogen). Before
adhesion assay, THP-1 cells were fluorescently labeled using Zynaxis PKH2
staining kit (Zynaxis Cell Sciences Inc.) according to a previously described
method (63). All steps were performed at 25°C. A suspension of THP-1
monocytic cells was incubated with 4 μM PKH-2GL for a labeling period of
5 minutes. The labeling was stopped by adding PBS containing 10% FCS.
Monocytic cells were incubated with 100 nM formyl-Met-Leu-Phe for 5
minutes. Activated monocytic cells were then incubated with the aortic segments at a concentration of 105 cells/well for 20 minutes at room temperature in an orbital shaker platform (Scienceware; Bel-Art Products). The aortic segments were then removed, gently washed in fresh K-H solution, and
placed lumen side up on a microscope slide. The aortic tissue was covered
with a drop of immersion oil followed by a glass coverslip. The number of
monocytic cells adhering to the endothelial surface in 4 separate microscopic fields was counted under epifluorescent microscopy at a magnification of
×200. Results are expressed as total number of cells/microscopic field.
Measurement of NO production in isolated aorta. Basal level of NO was
measured in WT mice, WT mice injected with TNF-α, and Ad–/– mice.
The effect of gAd on basal NO levels was also studied. Mouse thoracic
aorta rings, freshly isolated from donor mice, as described above, were
used as the source of primary endothelial cells for measurement of NO
production. The thoracic aortas were cut into 4-mm rings, which were
then opened and fixed by small pins with the endothelial surface facing
upwards in 24-well culture dishes containing 1 ml of prewarmed K-H
solution. After equilibration at 37°C, NO released into the K-H solution
was measured as previously reported (64). Briefly, a polarographic NO
electrode internally shielded to minimize external electrical interference
was connected to NO meter (Apollo 4000; World Precision Instruments).
Calibration of the NO electrode was performed daily prior to each experimental protocol as previously described (65). Standard calibration curve
was obtained by graded final concentrations of KNO2 from 0 to 500 nM
into a calibration solution containing 0.1 M potassium iodide and 0.1 M
H2SO4. Release of NO was expressed as pmol/mg of dry tissue.
Immunohistochemistry. Following intravital microscopy experiments, the
thorax was carefully opened, avoiding excessive bleeding. The vasculature
was then flushed to remove red blood cells by carefully injecting saline in
the left ventricle while the right ventricle was cut open for drainage (66).
Once the vasculature was free of red blood cells, mice were perfused with icecold 4% paraformaldehyde for 3–5 minutes. Sections of ileum (3–4 cm) were
then collected and placed in 4% paraformaldehyde for 2 hours on ice. The
tissue was then cut into rings, dehydrated by using graded acetone washes,
and embedded in plastic (Immunobed; Polysciences Inc.). Sections (5-μm
thick) were cut and transferred to Vectabond-coated slides (Vector Laboratories). Immunohistochemical localization of E-selectin and VCAM-1 was
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55:1537–1545.
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accomplished by using the avidin/ biotin immunoperoxidase technique
(Vectastain ABC Reagent: Vector Laboratories) and with mAbs against
either E-selectin or VCAM-1, as described previously (67). Briefly, blocking
serum (horse) was applied to the tissue for 30 minutes to reduce nonspecific
binding, and then the tissue sections were incubated with the primary antibody at a dilution of 1/100 for 24 hours. The tissue was then incubated with
the biotinylated secondary antibody, and peroxidase staining was carried out
using 3,3′-diaminobenzidine. Control preparations involved omission of the
primary antibody or omission of the secondary antibody. A total of 5 to 6
sections were studied from each mouse. Fifty venules were then analyzed per
tissue section, and the percentage of positive staining was determined.
Plasma measurements. Endogenous total adiponectin levels and levels
of the injected gAd in mouse serum were determined using mouse -and
human-specific immunoassay kits from R&D Systems. A drop of blood
was collected through tail vein puncture to measure blood glucose levels
using an Accu-Chek handheld glucose meter (Roche Diagnostics).
Reagents and solutions. Recombinant gAd was purchased from PeproTech.
Monoclonal antibodies to mouse E-selectin (10E9.6) and VCAM-1
(MR106) for immunohistochemistry were purchased from BD Biosciences. Isotype control for E-selectin antibody, rat IgG1, was purchased
from BD Biosciences — Pharmingen. Human recombinant TNF-α was
purchased from Sigma-Aldrich.
Statistics. All data are presented as mean ± SEM for the number of determinations shown in the figure or table. All data on leukocyte rolling and
adherence as well as on mean arterial blood pressure, shear rates, and NO
production levels were compared by ANOVA with post hoc analysis by
Neuman-Keuls corrected t test. P values of 0.05 or less were considered
statistically significant.
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